首页> 外文期刊>ACS Omega >Experimentally Validated QSAR Model for Surface pKa Prediction of Heterolipids Having Potential as Delivery Materials for Nucleic Acid Therapeutics
【24h】

Experimentally Validated QSAR Model for Surface pKa Prediction of Heterolipids Having Potential as Delivery Materials for Nucleic Acid Therapeutics

机译:实验验证的QSAR QSAR模型,其核酸治疗剂具有递送材料的杂脂的表面PKA预测

获取原文
           

摘要

The application of lipid-based drug delivery technologies for bioavailability enhancement of drugs has led to many successful products in the market for clinical use. Recent studies on amine-containing heterolipid-based synthetic vectors for delivery of siRNA have witnessed the United States Food and Drug Administration (USFDA) approval of the first siRNA drug in the year 2018. The studies on various synthetic lipids investigated for delivery of such nucleic acid therapeutics have revealed that the surface pK _(a) of the constructed nanoparticles plays an important role. The nanoparticles showing pK _(a) values within the range of 6–7 have performed very well. The development of high-performing lipid vectors with structural diversity and falling within the desired surface pK _(a) is by no means trivial and requires tedious trial and error efforts; therefore, a practical solution is called for. Herein, an attempt to is made provide a solution by predicting the statistically significant pK _(a) through a predictive quantitative structure–activity relationship (QSAR) model. The QSAR model has been constructed using a series of 56 amine-containing heterolipids having measured pK _(a) values as a data set and employing a partial least-squares regression coupled with stepwise (SW-PLSR) forward algorithm technique. The model was tested using statistical parameters such as r ~(2), q ~(2), and pred_r ~(2), and the model equation explains 97.2% (r ~(2) = 0.972) of the total variance in the training set and it has an internal (q ~(2)) and an external (pred_r ~(2)) predictive ability of ~83 and ~63%, respectively. The model was validated by synthesizing a series of designed heterolipids and comparing measured surface pK _(a) values of their nanoparticle assembly using a 2-(p -toluidino)-6-napthalenesulfonic acid (TNS) assay. Predicted and measured surface pK _(a) values of the synthesized heterolipids were in good agreement with a correlation coefficient of 93.3%, demonstrating the effectiveness of this QSAR model. Therefore, we foresee that our developed model would be useful as a tool to cut short tedious trial and error processes in designing new amine-containing heterolipid vectors for delivery of nucleic acid therapeutics, especially siRNA.
机译:脂质的药物递送技术在生物利用度增强药物的应用导致了许多临床用途的成功产品。最近关于含胺的杂项基础合成载体的研究表明,美国食品和药物管理局(USFDA)在2018年度批准了第一个SiRNA药物。研究各种合成脂质的研究,用于递送此类核酸治疗剂揭示了由构造的纳米颗粒的表面P K(A)起重要作用。显示在6-7范围内的p k _(a)值的纳米颗粒表现得非常好。具有结构多样性和落入所需表面P K _(a)的高性能脂质载体的发展绝不是琐碎的,需要繁琐的试验和误操作;因此,要求进行实际解决方案。这里,通过预测定量结构 - 活动关系(QSAR)模型来预测统计学上显着的P K _(a)来提供求解解决方案。 QSAR模型已经使用一系列56胺的含有含有测量的P K _(A)值作为数据集,并采用与逐步(SW-PLSR)前进算法技术耦合的部分最小二乘性回归。使用统计参数进行测试,例如 R〜(2), q〜(2)和pred_ R〜(2),并且模型方程解释了97.2%( r 〜(2)= 0.972)训练集的总方差,它具有内部( q〜(2))和外部(Pred_ r〜(2))预测能力〜83和〜63%。通过合成一系列设计的杂脂和使用2 - (β-丙磺基)-6-Napthalenesul磺酸(TNS)测定比较其纳米颗粒组件的测量表面P K(a)值与93.3%的相关系数吻合良好,证明了这种QSAR模型的有效性。因此,我们预见,我们的开发模式将作为一种工具,以削减乏味的试验和误差过程,用于设计含新的胺类杂脂载体,以便递送核酸治疗剂,尤其是siRNA。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号